Cortex Plans To Move CX717 Ahead In Other Indications Despite FDA Rejection For ADHD Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency denies Cortex investigational new drug application for a Phase IIb study of Ampakine compound CX717 in ADHD.